September S&P 500 futures (ESU22) are trending down -1.02% this morning after three major US benchmark indices resumed declines during the regular session as a variety of economic data failed to change...
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TYME Technologies, Inc. (NasdaqCM: TYME) to...
/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the...
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Syros Pharmaceuticals,...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of TYME Technologies, Inc. (NasdaqCM: TYME) to...
/PRNewswire/ -- Ademi LLP is investigating TYME (NASDAQ:TYME) for possible breaches of fiduciary duty and other violations of law in its transaction with Syros....
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and TYME Technologies, Inc. (NASDAQ:TYME), today announced that the companies have entered...
-- $84.0 million in cash and marketable securities as of March 31, 2022 --...
BEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company...